Head-to-head · WeighScore
LifespanningRx vs Omada Health
The verdict
LifespanningRx takes it — 60.4/100 to 55.6/100.
LifespanningRx grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. LifespanningRx is a clinician-guided longevity and peptide telehealth brand whose Weight Loss Program prescribes compounded GLP-1 (semaglutide/tirzepatide) injectables alongside peptide and healthy-aging…
We may earn a commission if you start care through some of these links, at no extra cost to you. It never moves the WeighScore, which is the weighted average of the six factors shown for every provider, and what we write about a provider is the same either way. See our disclosure.
Factor by factor
The same six graded dimensions, side by side. See the methodology.
The numbers
| Metric | LifespanningRx | Omada Health |
|---|---|---|
| WeighScore | 60.4/100 | 55.6/100 |
| Grade | C | C |
| Scorecard rank | #322 | #435 |
| Semaglutide | Not disclosed | Not disclosed |
| Tirzepatide | Not disclosed | Not disclosed |
| Coverage | All 50 states | Coverage not published |
| Brand-name access | Yes | Compounded only |
| Oral / sublingual | Injection only | Injection only |
Graded #322 · C
Strengths
- Compounded GLP-1 (semaglutide/tirzepatide) weight-loss program with licensed clinicians included
- LegitScript-certified and HIPAA-compliant; works with 503A/503B licensed US pharmacies
- Longevity and peptide protocols alongside weight loss; free membership, no monthly fee
- Discreet nationwide shipping with 24/365 support
- Also a turnkey white-label platform for clinics and wellness brands to launch programs
Where it loses points
- Exact dosing and pricing are shown only after completing the patient assessment
- Compounded GLP-1s are not FDA-approved finished products
- States served are not publicly listed
- Part B2B/white-label, so the consumer experience can vary by partnered clinic
Graded #435 · C
Strengths
- Added GLP-1 prescribing and medication management in late 2025
- Clinicians trained in obesity care, available in all 50 states
- Behavioral support wrapped before, during and after treatment
- GLP-1 Flex Care adds a cash-pay medication pathway in 2026
- Publicly traded, evidence-based virtual care platform
Where it loses points
- Core program distributed via employers and health plans, limited cash-pay
- GLP-1 prescribing is a recent addition still scaling
- GLP-1 Flex Care only rolling out to employers later in 2026
- No transparent published price for the core member program
Also worth a look
Neither is our top-graded pick — CoreAge Rx leads the scorecard
Across all 499 providers, CoreAge Rx grades highest at 91.8/100 (A−). Top of the scorecard: flat transparent pricing, both molecules, nationwide — no teaser-rate games.
Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.